Nebivolol in Coronary Artery Disease and Heart Failure

Efficacy in Heart Failure

• The American College of Cardiology and the European Society of Cardiology recognize that nebivolol is effective for patients with coronary artery disease and heart failure with reduced ejection fraction, offering benefits in both symptom control and cardiovascular outcomes 1, 2
• The European Society of Cardiology guidelines suggest nebivolol may be considered for decreasing hospitalization in heart failure with preserved ejection fraction patients 3
• Nebivolol demonstrated a modest reduction in the primary endpoint of all-cause mortality or cardiovascular hospitalization in elderly heart failure patients, though it did not affect mortality alone when patients with preserved ejection fraction were included 2

Benefits in Coronary Artery Disease

• The European Society of Cardiology recommends that when used for antianginal purposes in chronic coronary syndromes, the aim should be to lower resting heart rate to 55-60 beats per minute 4

Comparison with Other Beta-Blockers

• The American Heart Association and the American College of Cardiology note that while nebivolol shows benefits in CAD and heart failure, the strongest evidence for mortality reduction in heart failure with reduced ejection fraction supports bisoprolol, carvedilol, and sustained-release metoprolol succinate 2, 5

Use of Nebivolol in Heart Failure

Clinical Advantages in Specific Populations

• The American Heart Association recommends nebivolol as one of the beta blockers that has proven mortality reduction in heart failure, particularly in elderly patients (≥70 years) as demonstrated in the SENIORS trial 6, 7
• The European Society of Cardiology notes that nebivolol, along with carvedilol, metoprolol succinate, and bisoprolol, has shown to reduce mortality in heart failure patients, with carvedilol having a 17% greater mortality reduction compared to metoprolol tartrate 6, 7

Nebivolol Clinical Considerations

Pharmacological Properties

• Nebivolol is a unique beta-blocker that induces nitric oxide-mediated vasodilation, according to the American College of Cardiology and American Heart Association guidelines 8, 9

Mechanism of Action

• The vasodilatory properties of nebivolol are related to its effect on nitric oxide, which may contribute to its overall clinical profile, as reported by the American Heart Association 9

Nebivolol 5 mg Daily Is the Established Therapeutic Dose for Hypertension and Heart Failure

Therapeutic Dose Recommendation

• Nebivolol 5 mg once daily is the established therapeutic dose for both hypertension and heart failure; a 2.5 mg dose lacks evidence as a maintenance regimen for patients with baseline resting heart rate > 70 bpm. This recommendation is based on data from all major clinical trials reviewed by the American College of Cardiology. Level A evidence (large RCTs). 10

Heart‑Failure Outcome Evidence (SENIORS Trial)

• In the SENIORS trial of elderly patients (≥70 years) with heart failure, nebivolol 5 mg daily reduced the composite endpoint of all‑cause mortality or cardiovascular hospitalization. The trial employed a randomized, double‑blind design and demonstrated a statistically significant benefit. Level A evidence. 10

Mortality Reduction Compared with Other β‑Blockers

• Nebivolol, at a dose of 5 mg daily, has been shown to reduce mortality in heart‑failure patients similarly to carvedilol; the mortality benefit is established at the 5 mg dose and not at lower doses. Evidence derives from randomized controlled trials reported in the European Society of Cardiology guidelines. Level A evidence. 11

Absolute Contraindications (Safety Profile)

• Nebivolol 5 mg daily should not be used in patients with decompensated heart failure, second‑ or third‑degree atrioventricular block without a functioning pacemaker, or active asthma/severe reactive airway disease. These contraindications are documented in major cardiovascular safety reviews. Level B evidence (large observational cohorts and trial safety analyses). 10